Medtronic, Inc. (NYSE:MDT)

This company remains on the cutting edge of R&D for cardiac and medical devices. They consistently outperform their competitors.

Medtronic is going to dominate the spinal market. It's purchase of Kyphon will help to address vertebral compression fractures. Watch out for MDT to make other acquisitions in the VCF market like Orthovita (VITA, which also make bone graphing and surgical hemostat products)

Hey, they keep Mom alive.

a powerhouse. take it from a neurosurgeon.

Enough warning letters already!

Medtronic is slowly rising. Research funding is starting to pay off.

they help hearts.

I had one of thier defibrillators for years before a transplant and they are a solid company. Having dealt with heart failure and it's HUGE increaes in society this company can only thrive in the future as they are the premier ICD maker in N.A.

MDT is now sitting with a P/E of around 19.5, placing it below the average S&P ratio. It has virtually no debt, and commands an enormous 24% return on equity and 22.3% return on total capital. ValueLine has pegged it as one of their favorite company's for both the short term as well as in the coming 3 to 5 years projecting low price appreciation rates of 13% with highs around 20%.

My learning, as always, can be found here: http://learningtoinvestinvalue.com/MDT.aspx

070717: http://www.fda.gov/OHRMS/DOCKETS/98fr/E7-10267.htm

solid! dominate mkt share, cash cow, international demand & boomers keep it on top.To 60 + in 12 mths

I believe in this company's product and their excellent care for its customers. I have a pacemaker inplented in me and it's keeping me alive and active. Thank you Medtronic.

I don't think the stock will beat the street.

Innovative company in a growing industry

Medtronic has been hit by slower sales of implantable cardioverter defibrillators (ICD) but I think it will pick up within a year. Medtronic is performing well on other fronts like neurology.

Diabetes, pain management, and spinal repairs
are what this company does best--baby boomers
need is growing.

WHAT'S HAPPENING WITH MEDTRONIC? THIS IS THE BEST MEDICAL COMPANY IN THE US! THIS ONE IS A KEEPER

Expanded indications for defibrillator placement will become standard of care.
Medtronic will see tremendous growth in the diabetes and cardiac market.
Current value should be closer to $57 per share. Will parallel the S&P or outperform when it recovers from current dip.

Undervalued. Fair value is around $64